Skip to Content
Merck

Delamanid does not inhibit or induce cytochrome p450 enzymes in vitro.

Biological & pharmaceutical bulletin (2014-11-05)
Yoshihiko Shimokawa, Katsunori Sasahara, Noriaki Yoda, Katsuhiko Mizuno, Ken Umehara
ABSTRACT

Delamanid is a new drug for the treatment of multidrug-resistant tuberculosis. Individuals who are co-infected with human immunodeficiency virus and Mycobacterium tuberculosis may require treatment with a number of medications that might interact significantly with the CYP enzyme system as inhibitors or inducers. It is therefore important to understand how drugs in development for the treatment of tuberculosis will affect CYP enzyme metabolism. The ability of delamanid to inhibit or induce CYP enzymes was investigated in vitro using human liver microsomes or human hepatocytes. Delamanid (100 µM) had little potential for mechanism-based inactivation on eight CYP isoforms (CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, and CYP3A4). Delamanid's metabolites were noted to inhibit the metabolism of some CYP isoforms, but these effects were observed only at metabolite concentrations that were well above those observed in human plasma during clinical trials. Delamanid (≤10 µM) did not induce CYP1A2, CYP2C9, and CYP3A4 activities in human hepatocytes, and there were no increases in CYP1A2, CYP2B6, CYP2C9, and CYP3A4 mRNA levels. Taken together, these data suggest that delamanid is unlikely to cause clinically relevant drug-drug interactions when co-administered with products that are metabolized by the CYP enzyme system.

MATERIALS
Product Number
Brand
Product Description

USP
Nifedipine Nitrophenylpyridine Analog, United States Pharmacopeia (USP) Reference Standard
Paracetamol, European Pharmacopoeia (EP) Reference Standard
Supelco
Nifedipine, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
Oxidized Nifedipine, powder, ~95% (HPLC)
Sigma-Aldrich
6-Hydroxychlorzoxazone, ≥98% (HPLC)
Testosterone, European Pharmacopoeia (EP) Reference Standard
Supelco
Phenacetin melting point standard, Pharmaceutical Secondary Standard; Certified Reference Material
Supelco
Diclofenac sodium salt, Pharmaceutical Secondary Standard; Certified Reference Material
USP
Bupropion hydrochloride, United States Pharmacopeia (USP) Reference Standard
Supelco
Testosterone, VETRANAL®, analytical standard
Sigma-Aldrich
Phenacetin, ≥98.0% (HPLC)
Sigma-Aldrich
Hypoxanthine, ≥99.0%
Sigma-Aldrich
Bupropion hydrochloride, ≥98% (HPLC), solid
Sigma-Aldrich
Nifedipine, ≥98% (HPLC), powder
Sigma-Aldrich
Hypoxanthine, powder, BioReagent, suitable for cell culture
Sigma-Aldrich
Diclofenac sodium salt
Sigma-Aldrich
Resorufin, 95%
USP
Nifedipine, United States Pharmacopeia (USP) Reference Standard
Nifedipine, European Pharmacopoeia (EP) Reference Standard
USP
Phenacetin Melting Point Standard, United States Pharmacopeia (USP) Reference Standard
Supelco
Phenacetin, Pharmaceutical Secondary Standard; Certified Reference Material
Supelco
Testosterone solution, 1.0 mg/mL in acetonitrile, ampule of 1 mL, certified reference material, Cerilliant®
Sigma-Aldrich
Testosterone, ≥98%
Supelco
Diclofenac sodium salt, analytical standard
Diclofenac for system suitability, European Pharmacopoeia (EP) Reference Standard
Didanosine impurity A,, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
Umbelliferone, 99%
Sigma-Aldrich
Acetaminophen, meets USP testing specifications, 98.0-102.0%, powder
Sigma-Aldrich
Acetaminophen, analytical standard
Sigma-Aldrich
Chlorzoxazone